InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,554.13
(
1.07%
)
US TECH 100
18,728.00
(
2.08%
)
Dow Jones
40,861.71
(
0.31%
)
Brent Oil
70.82
(
0.43%
)
Bitcoin
58,424.49
(
1.88%
)
Post# of 253087
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120405
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech jim post# 183477

Tuesday, 01/27/2015 12:26:15 PM

Tuesday, January 27, 2015 12:26:15 PM

Post# of 253087
(REGN)—NVS starts phase-3 of RTH258 vs Eylea:

https://clinicaltrials.gov/ct2/show/NCT02307682

RTH258 is NVS’ next-generation anti-VEGF compound that may eventually be co-formulated with OPHT’s Fovista.

In the above trial, two doses of RTH258 are being tested. The primary endpoint is visual acuity at 48 weeks. Approximately 1000 patients are to be enrolled, randomized 1:1:1. Expected completion Jun 2018.

H/t ‘jq1234’.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up